Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H26FN3O4 |
| Molecular Weight | 403.4472 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN[C@@H](C)[C@@H]1CCN(C1)C2=C(F)C=C3C(=O)C(=CN(C4CC4)C3=C2OC)C(O)=O
InChI
InChIKey=SUQUWONDIBHQOZ-NWDGAFQWSA-N
InChI=1S/C21H26FN3O4/c1-11(23-2)12-6-7-24(9-12)18-16(22)8-14-17(20(18)29-3)25(13-4-5-13)10-15(19(14)26)21(27)28/h8,10-13,23H,4-7,9H2,1-3H3,(H,27,28)/t11-,12+/m0/s1
| Molecular Formula | C21H26FN3O4 |
| Molecular Weight | 403.4472 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Premafloxacin is an 8-methoxy fluoroquinolone derivative patented by American pharmaceutical company Warner-Lambert Co. as an antibacterial agent. In preclinical studied. Premafloxacin was equivalent to ciprofloxacin, enrofloxacin, and danofloxacin in activity against the gram-negative bacilli but was much more active than the comparison antimicrobial agents (against the staphylococci, streptococci, and anaerobes. Premafloxacin acts as a topoisomerase IV inhibitor with enhanced activity against Staphylococcus aureus.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:32:25 GMT 2025
by
admin
on
Mon Mar 31 21:32:25 GMT 2025
|
| Record UNII |
UOM2HMO524
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C795
Created by
admin on Mon Mar 31 21:32:25 GMT 2025 , Edited by admin on Mon Mar 31 21:32:25 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000081427
Created by
admin on Mon Mar 31 21:32:25 GMT 2025 , Edited by admin on Mon Mar 31 21:32:25 GMT 2025
|
PRIMARY | |||
|
C105016
Created by
admin on Mon Mar 31 21:32:25 GMT 2025 , Edited by admin on Mon Mar 31 21:32:25 GMT 2025
|
PRIMARY | |||
|
C66464
Created by
admin on Mon Mar 31 21:32:25 GMT 2025 , Edited by admin on Mon Mar 31 21:32:25 GMT 2025
|
PRIMARY | |||
|
DTXSID70162407
Created by
admin on Mon Mar 31 21:32:25 GMT 2025 , Edited by admin on Mon Mar 31 21:32:25 GMT 2025
|
PRIMARY | |||
|
CHEMBL2105374
Created by
admin on Mon Mar 31 21:32:25 GMT 2025 , Edited by admin on Mon Mar 31 21:32:25 GMT 2025
|
PRIMARY | |||
|
71455
Created by
admin on Mon Mar 31 21:32:25 GMT 2025 , Edited by admin on Mon Mar 31 21:32:25 GMT 2025
|
PRIMARY | |||
|
SUB10025MIG
Created by
admin on Mon Mar 31 21:32:25 GMT 2025 , Edited by admin on Mon Mar 31 21:32:25 GMT 2025
|
PRIMARY | |||
|
143383-65-7
Created by
admin on Mon Mar 31 21:32:25 GMT 2025 , Edited by admin on Mon Mar 31 21:32:25 GMT 2025
|
PRIMARY | |||
|
7333
Created by
admin on Mon Mar 31 21:32:25 GMT 2025 , Edited by admin on Mon Mar 31 21:32:25 GMT 2025
|
PRIMARY | |||
|
GG-29
Created by
admin on Mon Mar 31 21:32:25 GMT 2025 , Edited by admin on Mon Mar 31 21:32:25 GMT 2025
|
PRIMARY | |||
|
UOM2HMO524
Created by
admin on Mon Mar 31 21:32:25 GMT 2025 , Edited by admin on Mon Mar 31 21:32:25 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|